The role of CD95 and CD95 ligand in cancer.
The role of CD95 and CD95 ligand in cancer.
复制标题
CD95和CD95配体在癌症中的作用。
DOI：
10.1038/cdd.2015.3
复制
发表时间：
2015-04
影响因子：
12.4
通讯作者：
中科院分区：
文献类型：
--
作者：
CD95（Fas/APO-1）及其配体CD95L一直被认为是一个死亡受体/死亡配体系统，介导细胞凋亡诱导以维持免疫稳态。此外，这些分子在病毒感染细胞和癌细胞的免疫消除中很重要。因此，认为CD95L可用于癌症治疗。然而，主要的副作用已经排除了它的系统使用。在过去的10年中，人们已经认识到CD95和CD95L具有多种癌症相关的非凋亡和肿瘤促进活性。CD95和CD95L被发现是癌细胞的关键存活因子，并被发现保护和促进癌症干细胞。我们现在讨论五种不同的方式，其中抑制或消除CD95L，而不是增加，可能有利于单独或与标准化疗或免疫治疗联合的癌症治疗。
CD95 (Fas/APO-1) and its ligand, CD95L, have long been viewed as a death receptor/death ligand system that mediates apoptosis induction to maintain immune homeostasis. In addition, these molecules are important in the immune elimination of virus-infected cells and cancer cells. CD95L was, therefore, considered to be useful for cancer therapy. However, major side effects have precluded its systemic use. During the last 10 years, it has been recognized that CD95 and CD95L have multiple cancer-relevant nonapoptotic and tumor-promoting activities. CD95 and CD95L were discovered to be critical survival factors for cancer cells, and were found to protect and promote cancer stem cells. We now discuss five different ways in which inhibiting or eliminating CD95L, rather than augmenting, may be beneficial for cancer therapy alone or in combination with standard chemotherapy or immune therapy.
登录
查看更多内容
影响因子：
64.8
作者：
通讯作者：
--
影响因子：
16.6
作者：
Ceppi, Paolo;Hadji, Abbas;Kohlhapp, Frederick J.;Pattanayak, Abhinandan;Hau, Annika;Liu, Xia;Liu, Huiping;Murmann, Andrea E.;Peter, Marcus E.
通讯作者：
Peter, Marcus E.
激活的 T 细胞外泌体通过 Fas 信号通路促进肿瘤侵袭
影响因子：
4.4
作者：
Cai, Zhijian;Yang, Fei;Wang, Jianli
通讯作者：
Wang, Jianli
影响因子：
3.5
作者：
Chatzitolios, Anastasios;Venizelos, Ioannis;Papadopoulos, Nikolaos
通讯作者：
Papadopoulos, Nikolaos
DOI：
10.1053/ejso.2001.1223
发表时间：
2002-03-01
期刊：
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
影响因子：
--
作者：
Belluco, C;Esposito, G;Lise, M
通讯作者：
Lise, M